“The effectiveness of the vaccine consists of its immunological effectiveness and its prophylactic effectiveness. According to the results of the first and second phase of clinical trials, the immunological effectiveness of “Epivakorona” is 100 percent,” the message stated, BTA reported.
The presence of antibodies to the new coronavirus infection does not prevent vaccination with Epivakorona. Before immunization, however, it is necessary for a person to be fully recovered from the disease and to consult a doctor, said Rospotrebnadzor.
Data from the first and second phase of the Epivakorona trials were reported ahead of a move to the larger phase three, which should normally involve thousands of participants and a placebo group by comparison, Reuters reported.
First and second phase tests were carried out with 100 participants aged 18 to 60 years. Typically, these early human trials were based on indicators in the blood for an immune response, with participants not exposing themselves to the virus. Larger late-phase trials are based on actual instances of infection of volunteers in normal life.
Trials of “Epivakcorona” began in November.
Mass vaccination with “Epivakorona” will begin in Russia in March.
At the beginning of the month, Russia announced that its other Covid-19 vaccine Sputnik V had 92 percent efficiency based on intermediate results.
Immunological effectiveness of the Russian vaccine “Epivakorona” is 100%
The immunological effectiveness of Russia's Covid-19 Epivakkorona vaccine, developed by the Russian Vector Scientific Center of Virology and Biotechnology, is one hundred percent according to the results of the first two phases of clinical trials, TASS reported, citing Rospotrebnadzor's press service.tags: